Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05392881

Interstitial Lung Disease Research Unit Biobank

Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Interstitial Lung Disease Alveolitis, Extrinsic Allergic Fibrosis Hemic and Lymphatic Diseases Hypersensitivity Hypersensitivity Pneumonitis Hypersensitivity, Delayed Hypersensitivity, Immediate Idiopathic Pulmonary Fibrosis Immune System Diseases Lung Diseases Lung Diseases, Interstitial Lymphatic Diseases Lymphoproliferative Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Fibrosis Respiratory Hypersensitivity Respiratory Tract Diseases Sarcoidosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location status: Recruiting

Location contact

Chase Hall, M.D.

PRINCIPAL_INVESTIGATOR

Janell Reichuber, APRN

SUB_INVESTIGATOR

Kimberly Donnelly, Ph.D.

CONTACT

[email protected]

913-588-6067

Mark Hamblin, M.D.

SUB_INVESTIGATOR

Sahil Pandya, M.D

SUB_INVESTIGATOR

Scott Matson, M.D.

SUB_INVESTIGATOR

About this study

The University of Kansas ILD and Rare Lung Disease clinic sees hundreds of new patients per year. The investigators would like to leverage this resource to develop an Interstitial Lung Disease Research Unit (ILDRU) repository and database to help develop new methods for early diagnosis, uncover underlying genetic and environmental risk factors, as well as potential treatment targets in the broad range of interstitial lung diseases and rare lung diseases (RLD).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
  • The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
  • The participant is ≥ 18 years of age.
  • The participant has signed an approved consent for this study (living patients only)

Treatment and study plan

Primary outcomes

  1. Collect clinically obtained data for patients with ILD, RLD and risk for ILD/RLD to support research.

    Time frame: Enrollment to Year 10

  2. Establish a collection of biological samples from patients with ILD, RLD and subjects at risk for ILD.

    Time frame: Enrollment to Year 10

  3. Correlate biological samples with individual longitudinal clinical data.

    Time frame: Enrollment to Year 10

  4. Provide biological samples to researchers performing studies in ILD and RLD.

    Time frame: Enrollment to Year 10

  5. Collect historical data and imaging from deceased patients with ILD.

    Time frame: Enrollment to Year 10

Study contacts

Contact information is provided by the study sponsor or research team.

Kimberly Donnelly, Ph.D.

CONTACT

[email protected]

913-588-6067

Sponsors and collaborators

Lead sponsor

University of Kansas Medical Center

Other

Registry information

Official study title

University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank

Acronym: ILDRU

Important dates

Study start
2021
Primary completion
2031
Study completion
2032
First posted
May 26, 2022
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.